Immatics N.V. (IMTX)
NASDAQ: IMTX · IEX Real-Time Price · USD
10.89
0.00 (0.00%)
May 3, 2024, 11:34 AM EDT - Market open
Immatics Revenue
In the year 2023, Immatics had annual revenue of $60.00M, a decrease of -67.37%. Revenue in the quarter ending December 31, 2023 was $17.69M, a -55.83% decrease year-over-year.
Revenue (ttm)
$60.00M
Revenue Growth
-67.37%
P/S Ratio
18.69
Revenue / Employee
$112,143
Employees
535
Market Cap
1.12B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.00M | -123.87M | -67.37% |
Dec 31, 2022 | 183.86M | 144.36M | 365.44% |
Dec 31, 2021 | 39.50M | 1.39M | 3.65% |
Dec 31, 2020 | 38.11M | 17.38M | 83.86% |
Dec 31, 2019 | 20.73M | 16.40M | 378.37% |
Dec 31, 2018 | 4.33M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 1.82B |
Maravai LifeSciences Holdings | 288.95M |
MannKind | 198.96M |
Prothena Corporation | 91.37M |
Cronos Group | 87.24M |
AbCellera Biologics | 38.03M |
Silence Therapeutics | 32.12M |
Bicycle Therapeutics | 26.98M |
IMTX News
- 6 weeks ago - Immatics Announces Full Year 2023 Financial Results and Corporate Update - GlobeNewsWire
- 3 months ago - Immatics Announces Pricing of $175 Million Public Offering - GlobeNewsWire
- 3 months ago - Immatics Announces Proposed Public Offering - GlobeNewsWire
- 6 months ago - Immatics Announces Third Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 6 months ago - Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial - GlobeNewsWire
- 6 months ago - Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy - GlobeNewsWire
- 8 months ago - Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors - PRNewsWire
- 8 months ago - Immatics shares rise on Moderna cancer collaboration - Market Watch